Plasmodium vivax Controlled Human Malaria Infection – Progress and Prospects

Trends in Parasitology

Volumn 33, Issue 2, 2017, Pages 141-150

  Payne, Ruth O ^a   Griffin, Paul M ^b,c,d,e   McCarthy, James S ^b,e   Draper, Simon J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c Q Pharm Pty Ltd   (Australia)

^d MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

CHMI; IBSM; malaria; vivax

Indexed keywords

ANTIMALARIAL AGENT; MALARIA VACCINE;

APICOMPLEXAN LIFE CYCLE STAGE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED HUMAN MALARIA INFECTION; DISEASE MODEL; EXPERIENCE; EXPERIMENTAL INFECTION; HUMAN; MALARIA; MOSQUITO BITE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPOROZOITE; ANIMAL; BIOLOGICAL MODEL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MALARIA, FALCIPARUM; MALARIA, VIVAX; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; MODELS, BIOLOGICAL; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

EID: 85008174104     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2016.11.001     Document Type: Review

References (51)

1. 1 McCarthy, J.S., et al. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One, 6, 2011, e21914.
2. 2 Pasay, C.J., et al. Piperaquine monotherapy of drug-susceptible Plasmodium falciparum infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia. J. Infect. Dis. 214 (2016), 105–113.
3. 3 Sauerwein, R.W., et al. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 11 (2011), 57–64.
4. 4 Sheehy, S.H., et al. optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS One, 8, 2013, e65960.
5. 5 Engwerda, C.R., et al. Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol. 28 (2012), 515–521.
6. 6 Duncan, C.J., Draper, S.J., Controlled human blood stage malaria infection: current status and potential applications. Am. J. Trop. Med. Hyg. 86 (2012), 561–565.
7. 7 Duncan, C.J., et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel + CPG 7909. PLoS One, 6, 2011, e22271.
8. 8 Cheng, Q., et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am. J. Trop. Med. Hyg. 57 (1997), 495–500.
9. 9 Roestenberg, M., et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 88 (2013), 5–13.
10. 10 Mordmuller, B., et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malaria J., 14, 2015, 117.
11. 11 Stanisic, D.I., et al. Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malaria J., 14, 2015, 143.
12. 12 Teirlinck, A.C., et al. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J. Infect. Dis. 207 (2013), 656–660.
13. 13 Spring, M., et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 31 (2013), 4975–4983.
14. 14 Hodgson, S.H., et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front. Microbiol., 5, 2014, 686.
15. 15 Shekalaghe, S., et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 91 (2014), 471–480.
16. 16 Whitrow, M., Wagner-Jauregg and fever therapy. Med. History 34 (1990), 294–310.
17. 17 Snounou, G., Perignon, J.L., Malariotherapy – insanity at the service of malariology. Adv. Parasitol. 81 (2013), 223–255.
18. 18 Alving, A.S., et al. Procedures used at Stateville penitentiary for the testing of potential antimalarial agents. J. Clin. Invest. 27 (1948), 2–5.
19. 19 Coatney, H.R., et al. Studies in human malaria; trials of quinacrine, colchicine (SN 12,080) and quinine against Chesson strain vivax malaria. Am. J. Hyg. 50 (1949), 194–199.
20. 20 Miller, L.H., et al. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N. Engl. J. Med. 295 (1976), 302–304.
21. 21 Rieckmann, K.H., et al. Current considerations in vaccination of humans against malaria: Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull. Wld. Hlth. Organ. 57:Suppl. (1979), 261–265.
22. 22 Clyde, D.F., Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 24 (1975), 397–401.
23. 23 Clyde, D.F., et al. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 266 (1973), 398–403.
24. 24 McCarthy, V.C., Clyde, D.F., Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. Exp. Parasitol. 41 (1977), 167–171.
25. 25 Hoffman, S.L., et al. The march toward malaria vaccines. Am. J. Prev. Med. 49:6 Suppl. 4 (2015), S319–S333.
26. 26 Herrera, S., et al. Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am. J. Trop. Med. Hyg. 81 (2009), 740–746.
27. 27 Herrera, S., et al. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am. J. Trop. Med. Hyg. 84:2 Suppl. (2011), 4–11.
28. 28 Arevalo-Herrera, M., et al. Plasmodium vivax sporozoite challenge in malaria-naive and semi-immune Colombian volunteers. PLoS One, 9, 2014, e99754.
29. 29 Rojas-Pena, M.L., et al. Transcription profiling of malaria-naive and semi-immune Colombian volunteers in a Plasmodium vivax sporozoite challenge. PLoS Negl. Trop. Dis., 9, 2015, e0003978.
30. 30 Arevalo-Herrera, M., et al. Antibody Profiling in Naive and Semi-immune Individuals Experimentally Challenged with Plasmodium vivax Sporozoites. PLoS Negl. Trop. Dis., 10, 2016, e0004563.
31. 31 Arevalo-Herrera, M., et al. Protective efficacy of Plasmodium vivax radiation-attenuated sporozoites in Colombian volunteers: a randomized controlled trial. PLoS Negl. Trop. Dis., 10, 2016, e0005070.
32. 32 Bennett, J.W., et al. Phase 1/2a Trial of Plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy. PLoS Negl. Trop. Dis., 10, 2016, e0004423.
33. 33 Vanloubbeeck, Y., et al. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques. Vaccine 31 (2013), 6216–6224.
34. 34 Bennett, J.W., et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N. Engl. J. Med. 369 (2013), 1381–1382.
35. 35 McCarthy, J.S., et al. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J. Infect. Dis. 208 (2013), 1688–1694.
36. 36 Payne, R.O., et al. Demonstration of the blood-stage Plasmodium falciparum controlled human malaria infection model to assess efficacy of the P. falciparum apical membrane antigen 1 vaccine, FMP2.1/AS01. J. Infect. Dis. 213 (2016), 1743–1751.
37. 37 Griffin, P., et al. Safety and reproducibility of a clinical trial system using induced blood stage Plasmodium vivax infection and its potential as a model to evaluate malaria transmission. PLoS Negl. Trop. Dis., 10, 2016, e0005139.
38. 38 Vallejo, A.F., et al. Plasmodium vivax gametocyte infectivity in sub-microscopic infections. Malaria J., 15, 2016, 48.
39. 39 Pukrittayakamee, S., et al. Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria. Am. J. Trop. Med. Hyg. 79 (2008), 378–384.
40. 40 Kerlin, D.H., Gatton, M.L., A simulation model of the within-host dynamics of Plasmodium vivax infection. Malaria J., 14, 2015, 51.
41. 41 Roestenberg, M., et al. Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers. J. Infect. Dis. 206 (2012), 319–323.
42. 42 Spring, M., et al. Controlled human malaria infection. J. Infect. Dis. 209:Suppl. 2 (2014), S40–S45.
43. 43 Chulay, J.D., et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am. J. Trop. Med. Hyg. 35 (1986), 66–68.
44. 44 Ballou, W.R., et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1 (1987), 1277–1281.
45. 45 Herrington, D.A., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328 (1987), 257–259.
46. 46 Church, L.W., et al. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J. Infect. Dis. 175 (1997), 915–920.
47. 47 Berman, J.D., et al. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans. R. Soc. Trop. Med. Hyg. 95 (2001), 429–432.
48. 48 Shapiro, T.A., et al. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am. J. Trop. Med. Hyg. 60 (1999), 831–836.
49. 49 Somsak, V., et al. Transgenic Plasmodium parasites stably expressing Plasmodium vivax dihydrofolate reductase-thymidylate synthase as in vitro and in vivo models for antifolate screening. Malaria J., 10, 2011, 291.
50. 50 Mizutani, M., et al. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites. Infect. Immun. 82 (2014), 4348–4357.
51. 51 de Cassan, S.C., et al. Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein region II of Plasmodium Vivax. Front. Immunol., 6, 2015, 348.